Mainz Biomed (MYNZ) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

MYNZ · Stock Price

USD 0.35-2.10 (-85.53%)

Market Cap: $4.4M

Historical price data

Market Cap: $4.4MFounded: 2008HQ: Mainz, Germany

Sector Ranking#145 in Diagnostics & Precision Medicine #162 in Oncology (General)

Overview

Mainz Biomed is a commercial-stage molecular diagnostics company with a mission to transform cancer screening through convenient, at-home tests. Its core achievement is the CE-marked ColoAlert® test for colorectal cancer (CRC), which is marketed in Europe and is undergoing a pivotal FDA registration trial (ReconAAsense) in the U.S. The company's strategy is to penetrate the massive CRC screening market first, then leverage its platform for a multi-cancer early detection (MCED) pipeline, including pancreatic cancer. Recent corporate actions include a planned name change to Quantum Cyber and a $6.0 million private placement to fund operations.

Colorectal CancerPancreatic CancerMulti-Cancer Early Detection

Technology Platform

Proprietary PCR-based platform analyzing DNA methylation and mRNA biomarkers from non-invasive samples (stool/blood), integrated with machine learning/AI for early cancer detection.

Funding History

2

Total raised:$23.5M

PIPE$8.5MUndisclosedMar 15, 2023

IPO$15MUndisclosedNov 15, 2021

Opportunities

The multi-billion dollar colorectal cancer screening market presents a massive opportunity, especially in the U.S.

where adherence is low.

Success in the ReconAAsense trial could position ColoAlert as a high-performance competitor.

Early research into pancreatic cancer and MCED tests offers significant long-term optionality in rapidly growing diagnostic segments.

Risk Factors

The company faces imminent financial risk with a limited cash runway, requiring dilutive financing.

The pivotal ReconAAsense trial carries high clinical and regulatory risk; failure would be catastrophic.

Commercialization against the dominant U.S.

competitor, Exact Sciences, presents a formidable challenge even with FDA approval.

Competitive Landscape

Mainz Biomed's primary competitor in the U.S. is Exact Sciences' Cologuard, which has a dominant market position. In the broader cancer detection space, it faces GRAIL (Illumina) in MCED and numerous liquid biopsy companies. Mainz's differentiation lies in its proprietary biomarker panels, European commercial base, and qPCR-based platform economics.